Search

Your search keyword '"J. Provencal"' showing total 4 results
Start Over Author "J. Provencal" Search Limiters Peer Reviewed
4 results on '"J. Provencal"'

1. A Search for QPOs in the Blazar OJ287: Preliminary Results from the 2015/2016 Observing Campaign

Author

S. Zola, M. Valtonen, G. Bhatta, A. Goyal, B. Debski, A. Baran, J. Krzesinski, M. Siwak, S. Ciprini, A. Gopakumar, H. Jermak, K. Nilsson, D. Reichart, K. Matsumoto, K. Sadakane, K. Gazeas, M. Kidger, V. Piirola, F. Alicavus, K. S. Baliyan, A. Berdyugin, D. Boyd, M. Campas Torrent, F. Campos, J. Carrillo Gómez, D. B. Caton, V. Chavushyan, J. Dalessio, D. Dimitrov, M. Drozdz, H. Er, A. Erdem, A. Escartin Pérez, V. Fallah Ramazani, A. V. Filippenko, F. Garcia, F. Gómez Pinilla, M. Gopinathan, J. B. Haislip, J. Harmanen, R. Hudec, G. Hurst, K. M. Ivarsen, M. Jelinek, A. Joshi, M. Kagitani, N. Kaur, W. C. Keel, A. P. LaCluyze, B. C. Lee, E. Lindfors, J. Lozano de Haro, J. P. Moore, M. Mugrauer, R. Naves Nogues, A. W. Neely, R. H. Nelson, W. Ogloza, S. Okano, J. C. Pandey, M. Perri, P. Pihajoki, G. Poyner, J. Provencal, T. Pursimo, A. Raj, R. Reinthal, S. Sadegi, T. Sakanoi, Sameer, J.-L. Salto González, T. Schweyer, F. C. Soldán Alfaro, N. Karaman, E. Sonbas, I. Steele, J. T. Stocke, J. Strobl, L. O. Takalo, T. Tomov, L. Tremosa Espasa, J. R. Valdes, J. Valero Pérez, F. Verrecchia, J. R. Webb, M. Yoneda, M. Zejmo, W. Zheng, J. Telting, J. Saario, T. Reynolds, A. Kvammen, E. Gafton, R. Karjalainen, and P. Blay

Subjects
galaxies: active, BL Lacertae objects: individual (OJ287), supermassive black holes, Astronomy, QB1-991
Abstract

We analyse the light curve in the R band of the blazar OJ287, gathered during the 2015/2016 observing season. We did a search for quasi-periodic oscillations (QPOs) using several methods over a wide range of timescales. No statistically significant periods were found in the high-frequency domain both in the ground-based data and in Kepler observations. In the longer-period domain, the Lomb–Scargle periodogram revealed several peaks above the 99% significance level. The longest one—about 95 days—corresponds to the innermost stable circular orbit (ISCO) period of the more massive black hole. The 43-day period could be an alias, or it can be attributed to accretion in the form of a two-armed spiral wave.

Published
2016
Full Text
View/download PDF

2. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trial

Author

A. Laplanche, Thierry Lesimple, E. Blot, M. Gross-Goupil, Frank Priou, Nicolas Penel, Karim Fizazi, Sylvie Negrier, A. Fourcade, J. Provencal, Eric Voog, Marie-Christine Kaminsky, Alain Lortholary, Stéphane Culine, Loic Chaigneau, and J. Bouzy

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Urology, Neutropenia, Deoxycytidine, Disease-Free Survival, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival rate, Aged, Cisplatin, Chemotherapy, Performance status, business.industry, Middle Aged, medicine.disease, Gemcitabine, Confidence interval, Survival Rate, Log-rank test, Neoplasms, Unknown Primary, Female, business, medicine.drug
Abstract

Purpose To compare the overall survival rates of good-prognosis carcinomas of an unknown primary site (CUPS) patients treated with cisplatin alone (C) or in combination with gemcitabine (CG). Patients and methods Good prognosis was defined according to the GEFCAPI (Groupe d’Etude Francais des Carcinomes de site Primitif Inconnu) classification by PS (Performance Status) ⩽1 and LDH (Lactate Deshydrogenase) within the normal range. Patients were randomly assigned to receive C or CG. Patients in the C arm received cisplatin 100 mg/m2 repeated every 3 weeks. In the CG arm, chemotherapy consisted of gemcitabine 1250 mg/m2 on days 1 and 8 and cisplatin 100 mg/m2 IV on day 1, repeated every 3 weeks. The original plan was to accrue 192 patients in order to detect a 20% difference in overall survival. Results Fifty-two patients were enrolled (arm A: 25; arm B: 27). The trial was stopped early due to insufficient accrual. The median overall survival (OS) rate was 11 months [95% confidence interval: 9–20] and 8 months [95% CI: 6–12], in the CG arm and in the C arm, respectively. The 1-year survival rate was 46% [95% CI: 28–64] in the combination arm and 35% [95% CI: 19–56] in the C arm (log rank test: p = 0.73). The median progression-free survival (PFS) rate was 5 [95% CI: 3–11] and 3 [95% CI: 1–8] months in the CG and in the C arm, respectively. The 1-year PFS rate was 29% [95% CI: 15–48] in the combination arm and 15% [95% CI: 5–35] in the C arm (log rank test: p = 0.27). No toxic deaths occurred. Grade 3–4 neutropenia (63% versus 12%) and grade 3–4 thrombocytopenia (37% versus 4%) were more frequent in the CG arm than in the C arm. Conclusion A non-significantly better outcome was observed with CG as compared to C in patients with CUP and a non-unfavourable prognosis. The toxicity profile of the combined arm was represented by haematologic toxicity with thrombocytopenia and leuconeutropenia. International collaboration is required to conduct phase III trials in patients with CUP.

Published
2012
Full Text
View/download PDF

3. Optic neuritis associated with sunitinib

Author

M. E. Deschamps and J. Provencal

Subjects
Gynecology, medicine.medical_specialty, Oncology, business.industry, Sunitinib, medicine, business, medicine.drug
Abstract

Les traitements antiangiogeniques occupent une place croissante en oncologie. La frequence de leur utilisation induit l’apparition d’effets secondaires jusqu’alors sous-estimes, notamment neurologiques. Nous rapportons un cas de nevrite optique attribuee au traitement par sunitinib chez une patiente atteinte d’un cancer du rein.

Published
2012
Full Text
View/download PDF

4. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.

Author

O Trédan, J-F Geay, S Touzet, R Delva, B Weber, J Cretin, J Provencal, J Martin, L Stefani, E Pujade-Lauraine, and G Freyer

Subjects
*DRUG therapy, *OLDER patients, *OVARIAN cancer, *CANCER patients, *PACLITAXEL
Abstract

Background: To determine the feasibility of two chemotherapy regimens in elderly patients with advanced ovarian carcinoma (AOC).Patients and methods: Eighty-three patients ≥70 years were previously enrolled in a trial evaluating carboplatin and cyclophosphamide (CC). On the basis of identical eligibility criteria, 75 further patients were enrolled in a trial evaluating carboplatin and paclitaxel (Taxol) (CP). The primary end point of these studies was the feasibility of six courses of chemotherapy. Comprehensive geriatric assessment (CGA) parameters were assessed in terms of prognostic factors.Results: More patients in the CC group presented with performance status of two or more, depression symptoms, use of co-medications, hypoalbuminemia, abnormal Mini-Mental Status score, or sub-optimal surgery. Both regimens appeared feasible: 75.6% in the CC group and 68.1% in the CP group completed six courses. CC and CP groups had similar overall survival (OS). Independent prognostic factors of poorer OS were the following: increasing age (P = 0.013), depression symptoms at baseline (P < 0.001), International Federation of Gynecology and Obstetrics stage IV (P = 0.001), and use of paclitaxel (P = 0.025).Conclusion: As this is a non-randomised retrospective review of two consecutive studies, no firm conclusion can be drawn. It seems, however, that in elderly patients with AOC the use of paclitaxel results in more toxicity. CGA parameters and particularly emotional disorders might help to determine a priori the risk/benefit ratio of chemotherapy in this patient population. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results